Norspan (Buprenorphine)

Buprenorphine binds partially to µ‑opioid receptors, activating them to produce analgesia while limiting maximal respiratory depression. It also blocks κ‑opioid receptors, which contributes to its pain‑relieving profile. The transdermal system releases the drug slowly, maintaining steady plasma levels over several days.

The specific dose of Norspan is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and clinical response. Available patch strengths are 5 µg/h, 10 µg/h, 15 µg/h, and 20 µg/h, each applied once every 7 days.

Safety data for buprenorphine transdermal patches in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless no safer alternatives are available.

To request Norspan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Norspan’s buprenorphine patch offers a partial µ‑opioid agonist profile, which provides a ceiling effect for respiratory depression compared with full agonist patches such as fentanyl. This can result in a slightly lower risk of severe respiratory compromise, though both require careful monitoring.

Store Norspan patches at room temperature, below 25 °C, in their original sealed pouch. Keep them away from moisture, direct sunlight and heat sources. Do not expose patches to temperatures above the recommended range, as this may affect drug stability.

The patch is applied to clean, dry, hair‑free skin on the upper torso or upper arm. Press firmly for at least 30 seconds, then cover with a protective dressing if needed. The patch remains in place for 7 days and is then replaced with a new one at a different site.

Serious risks include respiratory depression, severe hypotension, opioid dependence, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention if they experience difficulty breathing, extreme drowsiness, or unusual skin changes.

Norspan is contraindicated in patients with known hypersensitivity to buprenorphine or any patch components, in those with severe respiratory insufficiency, acute asthma attacks, or in patients who are opioid‑naïve and require rapid analgesia. Caution is also advised for individuals with significant hepatic impairment.